EULAR/ACR特发性炎症性肌病分类标准在日本队列中的首次外部验证
该研究纳入420例IIM和402例非IIM病例,外部验证EULAR/ACR分类标准的敏感性和特异性。以55%概率为切点时,总队列敏感性/特异性为89.3%/91.0%,且在PM/DM分类中优于既往标准。
要点
- 总队列中EULAR/ACR标准敏感性/特异性为89.3%/91.0%。
- 无肌活检数据时特异性达95.1%,有活检数据时为65.5%。
- PM/DM分类敏感性/特异性优于修订的Tanimoto标准。
核心结论
- 新标准在日本队列中外部验证显示高特异性,且对PM/DM分类的敏感性和/或特异性优于既往标准。
研究设计与样本
- 研究纳入420例IIM和402例非IIM病例,采用EULAR/ACR推荐的55%概率切点计算敏感性和特异性。
主要发现
- 总队列敏感性/特异性为89.3%/91.0%,无肌活检数据时为88.1%/95.1%,有活检数据时为90.4%/65.5%。
- 有活检数据的12例重叠综合征患者按传统日本方法归为非IIM时特异性为65.5%,归为IIM时特异性升至74.4%。
- PM/DM(含幼年和无肌病性DM)分类敏感性/特异性为87.4%/92.4%,优于修订Tanimoto标准(71.2%/87.8%),与Bohan & Peter标准(88.4%/88.3%,不含ADM)相当。
关键数值与推荐
- EULAR/ACR推荐的概率切点为55%。
- 总队列敏感性/特异性:89.3%/91.0%。
- 无肌活检数据敏感性/特异性:88.1%/95.1%;有活检数据:90.4%/65.5%。
- PM/DM分类敏感性/特异性:87.4%/92.4%。
临床怎么用
- 新标准可用于日本人群IIM分类,尤其无肌活检数据时特异性高。
- 有肌活检数据时特异性较低,需注意重叠综合征的归类影响。
局限性
- 儿童患者比例低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To externally validate the performance of the new European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria set for idiopathic inflammatory myopathies (IIM) with a Japanese cohort. METHODS: This study included 420 IIM and 402 non-IIM cases. Probability of having IIM in each patient was calculated using the collected data set. The cut-off probability was set at 55%, as recommended by EULAR/ACR. Patients classified as IIM by the criteria were further subclassified with classification trees. RESULTS: When the probability cut-off was set at 55%, the sensitivity/specificity of the new criteria to diagnose IIM were 89.3%/91.0% in the total cohort, 88.1%/95.1% without muscle biopsy data and 90.4%/65.5% with biopsy data. The cohort included 12 overlap syndrome patients with biopsy data, who were included as non-IIM cases in accordance with traditional Japanese methods. When they were included in the IIM cases, the specificity in patients with biopsy increased to 74.4%. The sensitivity/specificity of the new criteria to diagnose polymyositis/dermatomyositis (PM/DM) plus juvenile and amyopathic DM in the Japanese cohort was 87.4%/92.4%, which were greater than those of the Tanimoto's criteria revised to enable classification of amyopathic DM (ADM) (71.2%/87.8%) and were comparable with those of Bohan & Peter's criteria to diagnose those diseases except for ADM (88.4%/88.3%). CONCLUSIONS: Our study externally validated high specificity of the new criteria for the first time, although with several limitations, including low percentage of child patients. The new criteria have higher sensitivity and/or specificity in classification of PM/DM than the previously reported criteria, demonstrating its usefulness for interethnic patients.
引用
- Jinnin M, Ohta A, Ishihara S, et al. First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort. Ann Rheum Dis. 2019. PMID: 31694813. doi:10.1136/annrheumdis-2019-215488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。